Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-97489 PET Imaging Study
NCT05065541Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bms-986368 in epilepsy, multiple sclerosis (MS) and agitation (3 arms), sponsored by Celgene Corporation. Primary endpoints: Radiation dosimetry calculated from PET-CT images at 1 day, Calculated % Injected Dose in brain and other key organs and tissues at 1 day and 3 more. Started Sep 2021; status: completed.
02
Drugs
bms-986368
03
Conditions
epilepsymultiple sclerosis (MS)agitation
Beyond the preview
Go deeper on NCT05065541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065541.